Rapamycin
Sirolimus
Rapamycin (sirolimus) is the only pharmacologic agent that has reproducibly extended mammalian lifespan. Originally an immunosuppressant for transplant patients, it inhibits mTORC1 and activates autophagy. Weekly off-label dosing is the most studied longevity protocol, though human outcomes data remain limited.
mTORC1 inhibitor (macrolide)Prescription requiredEvidence C
⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.
Why it matters
Rapamycin extends lifespan in every model organism tested - yeast, worms, flies, and mice - through inhibition of the mTORC1 nutrient-sensing pathway. The landmark Nature 2009 study from the NIA Interventions Testing Program showed rapamycin extended median lifespan in genetically heterogeneous mice even when started in old age, an effect replicated multiple times. Mechanistically, mTORC1 inhibition reduces protein translation, downregulates lipogenesis, and activates autophagy and lysosomal clearance of damaged organelles. In humans, daily high-dose rapamycin is FDA-approved for organ transplant and LAM but causes infections, hyperlipidemia, and stomatitis. The off-label longevity protocol pioneered by Mikhail Blagosklonny and popularized by Peter Attia uses weekly low doses (typically 5-8 mg) to preferentially inhibit mTORC1 while sparing mTORC2-dependent immune and insulin signaling. Mannick et al. demonstrated that TORC1 inhibition enhanced influenza vaccine response in older adults. The PEARL trial is testing safety and biomarker effects in healthy adults. For longevity-curious men comfortable with experimental risk, rapamycin sits at the frontier of geroscience pharmacology - high mechanistic confidence, modest human outcome data.
Uses
Label uses (approved)
- Prophylaxis of organ rejection in renal transplant
- Lymphangioleiomyomatosis (LAM)
- Coronary stent coating to prevent restenosis
Off-label (educational only)
- Healthspan and longevity extension — Only pharmacologic intervention that has reproducibly extended lifespan in mammals (ITP studies in mice, Nature 2009 and follow-ups). Mechanism conserved across species.
- Immunosenescence reversal — Mannick et al. trials showed everolimus (analog) improved influenza vaccine response in older adults
- Periodontal aging (TAME-style outcome) — PEARL trial (NCT04488601) testing efficacy on aging biomarkers in healthy adults
Dosing
Label dose
2 mg orally once daily (transplant); LAM 2 mg daily titrated to trough 5-15 ng/mL
Off-label / biohacker dose
5-8 mg orally once weekly is the most common longevity protocol (Attia, Blagosklonny school); some clinicians use 6 mg every 2 weeks; not formally validated in randomized longevity trials
Titration: Intermittent weekly dosing is hypothesized to preferentially inhibit mTORC1 (longevity-relevant) while sparing mTORC2 (insulin signaling, immune function). Start low (3-4 mg weekly) and titrate. Take on an empty stomach with consistent fat content (food increases absorption variability). Avoid grapefruit. Many longevity clinicians cycle (e.g., 3 months on, 1 month off).
When to take: Weekly dosing: same day each week, on an empty stomach, with grapefruit avoided. Some clinicians dose in the evening to align trough with the morning insulin sensitivity window.
Side effects & warnings
Common
- Mouth ulcers (stomatitis, dose-related)
- Mild hyperlipidemia (triglycerides and LDL-C rise)
- Mild insulin resistance
- Lower extremity edema
- Acne-like rash
Uncommon but serious
- Increased infection risk at chronic high doses
- Pneumonitis (rare, immediate discontinuation if suspected)
- Wound healing impairment
- Proteinuria
- Thrombocytopenia
- Anemia
Serious warnings
Pneumonitis is a class-specific serious adverse event - new respiratory symptoms warrant immediate evaluation. Avoid pre-surgical use due to wound healing impairment (hold 2-3 weeks before elective surgery). Live vaccines should be deferred. Long-term immunosuppression risk at high chronic doses; intermittent low-dose longevity protocols have far smaller infection signal in observational data but lack outcome trials.
Biomarkers affected
fasting glucose
variableCan induce mild insulin resistance via mTORC2 effects, particularly with daily dosing
Evidence: moderate
hscrp
variableAnti-inflammatory effects via autophagy induction; clinical hsCRP data limited
Evidence: weak
igf 1
variablemTORC1 inhibition reduces IGF-1 signaling downstream; clinical IGF-1 changes modest and inconsistent
Evidence: weak
ldl c
variableModest LDL-C increase observed in transplant dosing; smaller magnitude at intermittent low doses
Evidence: moderate
triglycerides
variableIncreases triglycerides ~10-20% via mTORC1-mediated lipogenesis effects; documented in transplant cohorts
Evidence: moderate
Monitoring
Lipid panel, fasting glucose/insulin, HbA1c, CBC, urinalysis at baseline and every 3-6 months. Trough sirolimus level (5-15 ng/mL window) for transplant indications; longevity protocols rarely require trough monitoring at weekly doses.
The honest risk picture
Rapamycin in transplant use clearly increases infections, impairs wound healing, raises triglycerides and LDL-C, and induces mild insulin resistance. The weekly low-dose longevity protocol substantially reduces these risks but does not eliminate them. Stomatitis (mouth ulcers) is the most common dose-limiting side effect - usually manageable by reducing the dose. Lipid changes typically include 10-20% increases in triglycerides and modest LDL-C elevation; coadministering a statin is common in longevity practice. Insulin resistance is generally mild on weekly dosing but should be monitored. The most serious class-specific risk is interstitial pneumonitis - new cough or dyspnea requires immediate evaluation. Wound healing is impaired, so the drug should be held 2-3 weeks before and after elective surgery. Live vaccines should be deferred. Long-term outcome data in healthy adults using intermittent dosing are limited; the off-label longevity protocol is genuinely experimental. Drug interactions are significant: avoid grapefruit (CYP3A4 inhibition raises levels), strong CYP3A4 inhibitors (ketoconazole, ritonavir), and use caution with statins (some increase rapamycin exposure). Patients on rapamycin should disclose use before any surgery, vaccination, or new prescription.
Practical context
Cost (US, retail)
$300/mo
Legality
FDA-approved for transplant and LAM only. Longevity use is off-label and not endorsed by FDA. Legal to prescribe off-label in the US.
Interactions
true
FAQ
Is rapamycin proven to extend human lifespan?+
No. It extends lifespan in every model organism tested including mice (ITP studies), but human longevity outcomes data do not exist. Use in healthy adults is experimental and off-label. The PEARL trial (NCT04488601) is testing safety and biomarker effects in healthy adults.
Why weekly instead of daily?+
Daily dosing inhibits both mTORC1 (longevity target) and mTORC2 (insulin signaling and immunity). Intermittent weekly dosing is hypothesized to preferentially inhibit mTORC1, capturing longevity benefits while minimizing metabolic and immune downsides. This remains a hypothesis, not a proven strategy.
What about infection risk?+
Chronic high-dose use in transplant patients clearly increases infections. Intermittent low-dose use in healthy adults shows much smaller signals in observational cohorts. Outcome trials are not yet available.
The prime report
Weekly performance intelligence.
New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.